Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Verrica Pharmaceuticals (VRCA) Amortization of Deferred Charges (2021)

Verrica Pharmaceuticals has reported Amortization of Deferred Charges over the past 1 years, most recently at $58000.0 for Q4 2021.

Quarterly results put Amortization of Deferred Charges at $58000.0 for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $228000.0 (changed N/A YoY), and the annual figure for FY2021 was $228000.0, up 22.58%.
Amortization of Deferred Charges for Q4 2021 was $58000.0 at Verrica Pharmaceuticals, up from $57000.0 in the prior quarter.
Over the last five years, Amortization of Deferred Charges for VRCA hit a ceiling of $58000.0 in Q4 2021 and a floor of $56000.0 in Q1 2021.